Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
Healthcare
$6.98 +1.28%
+$0.16 today
- Market cap
- $150.57M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
52W Low $11.40High $16.77
Volume 0.23M
Average 0.35M
Income Statement
Follow revenue through to earnings.
Revenue
$18.62M
FY 2025 · Annual
Operating Income
-$76.81M
FY 2025 · Annual
Net Income
-$76.68M
FY 2025 · Annual
Income Statement
USD
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 18.62M |
| Cost of Revenue | 0 |
| Gross Profit | 18.62M |
| Gross Margin | 100.0% |
| Research & Development | 53.76M |
| Selling, General & Admin | 41.68M |
| Operating Expenses | 95.43M |
| Depreciation & Amortization | 323K |
| EBITDA | (76.5M) |
| EBITDA Margin | -410.9% |
| Operating Income | (76.81M) |
| Operating Margin | -412.6% |
| Interest Income | 0 |
| Interest Expense | 0 |
| Other Income / Expenses | (12K) |
| Income Before Tax | (76.83M) |
| Pre-Tax Margin | -412.6% |
| Income Tax Expense | (142K) |
| Net Income | (76.68M) |
| Net Margin | -411.9% |
| EPS (Basic) | (4.48) |
| EPS (Diluted) | (4.48) |
| 17.11M | |
| 17.11M |
RNA Earnings Waterfall · TTM
NASDAQ:RNA · Revenue to Net Income
No earnings data available.
Competitors
Peer companies in the same sector
No competitor data available.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 2, 2026 | |
| 8-K | Current report | Oct 27, 2026 | |
| 8-K/A | 8-K/A filing | Oct 9, 2026 |
How much revenue does RNA generate?
Atrium Therapeutics, Inc. (RNA) reported $18.62M of revenue in fiscal 2025.
Is RNA profitable?
Atrium Therapeutics, Inc. (RNA) reported -$76.68M of net income, with a net margin of -411.9%.
Continue the stock analysis
Jump to another research area for this company.